Suven Life Sciences Board of Directors

Get the latest insights into the leadership at Suven Life Sciences. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Venkateswarlu Jasti Chairman & Managing Director
Mrs. Sudharani Jasti Whole Time Director
Prof. Seyed E Hasnain Director
Mr. Santanu Mukherjee Director
Mrs. J A S Padmaja Director
Dr. Vajja Sambasiva Rao Director

Suven Life Sciences Share price

SUVEN

211.67

3.70 (-1.72%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:45 IST
BUYSELL
Today's High

220.10

Today's Low

210.00

52 Week Low

102.50

52 Week High

299.99

The current prices are delayed, login to your account for live prices

Suven Life Sciences FAQs

The board at Suven Life Sciences consists of experienced professionals, including Mr. Venkateswarlu Jasti , Mrs. Sudharani Jasti , and others, overseeing the company’s strategic and corporate governance.

Directors at Suven Life Sciences are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Venkateswarlu Jasti is the current chairman at Suven Life Sciences.

Executive directors at Suven Life Sciences are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Suven Life Sciences adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Suven Life Sciences, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.